UBRELVY (nda211765)- (50MG,100MG)

Generic Name	UBROGEPANT	Innovator	ABBVIE
Dosage	50MG,100MG
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2041-Dec-22	NCE Excl Expiry	2024-Dec-23
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	5

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
50MG	**	**	Up	-	-
100MG	**	**	Up	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of UBRELVY